Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor α in autoimmune hemolytic anemia and participate in Th17 polarization
Marion Ciudad,
Sethi Ouandji,
Baptiste Lamarthée,
Claudie Cladière,
Thibault Ghesquière,
Martin Nivet,
Marine Thébault,
Romain Boidot,
Agnès Soudry-Faure,
Sandy Chevrier,
Corentin Richard,
Thibault Maillet,
François Maurier,
Hélène Greigert,
Coraline Genet,
André Ramon,
Malika Trad,
Valérie Predan,
Philippe Saas,
Maxime Samson,
Bernard Bonnotte,
Sylvain Audia
Affiliations
Marion Ciudad
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Sethi Ouandji
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Baptiste Lamarthée
Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Claudie Cladière
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Thibault Ghesquière
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Martin Nivet
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Marine Thébault
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Romain Boidot
Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon
Agnès Soudry-Faure
Department of Clinical Research and Innovation (DRCI), Clinical Research Unit-Methodological Support Network (USMR), Dijon Bourgogne University Hospital, Dijon
Sandy Chevrier
Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon
Corentin Richard
Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon
Thibault Maillet
Department of Internal Medicine - Centre Hospitalier de Mâcon, Groupe Hospitalier Bourgogne Méridionale - F-71000 Macon
François Maurier
Department of Internal Medicine, Groupe Hospitalier UNEOS - F-57000 Metz
Hélène Greigert
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Coraline Genet
Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
André Ramon
Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Malika Trad
Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Valérie Predan
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon
Philippe Saas
Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Maxime Samson
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Bernard Bonnotte
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Sylvain Audia
Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon
Warm autoimmune hemolytic anemia (wAIHA) is a rare acquired autoimmune disease mediated by antibodies targeting red blood cells. The involvement of CD4 T-helper cells has been scarcely explored, with most findings extrapolated from animal models. Here, we performed quantification of both effector T lymphocytes (Teff) and regulatory T cells (Treg), associated with functional and transcriptomic analyses of Treg in human wAIHA. We observed a shift of Teff toward a Th17 polarization concordant with an increase in serum interleukin-17 concentration that correlates with red blood cell destruction parameters, namely lactate dehydrogenase and bilirubin levels. A decrease in circulating Treg, notably effector Treg, associated with a functional deficiency, as represented by their decrease capability to inhibit Teff proliferation, were also observed. Treg deficiency was associated with a reduced expression of Foxp3, the master transcription factor known to maintain the Treg phenotype stability and suppressive functions. Transcriptomic profiling of Treg revealed activation of the tumor necrosis facto (TNF)-α pathway, which was linked to increased serum TNF-α concentrations that were twice as high as in controls. Treg transcriptomic profiling also suggested that post-translational mechanisms possibly accounted for Foxp3 downregulation and Treg dysfunctions. Since TNF-α participates in the rupture of immune tolerance during wAIHA, its inhibition could be of interest. To this end, the effects of fostamatinib, a SYK inhibitor, were investigated in vitro, and we showed that besides the inhibition of erythrocyte phagocytosis by monocytes, fostamatinib is also able to dampen TNF-α production, thus appearing as a promising multitargeting therapy in wAIHA (clinicaltrials gov. Identifier: NCT02158195).